Literature DB >> 29311728

Editorial: Itching to Know: Role of Fibrates in PBC.

Cynthia Levy1, Keith D Lindor2.   

Abstract

Approximately one-third of patients with primary biliary cholangitis (PBC) fail to respond to ursodeoxycholic acid (UDCA) and are at risk for progression to biliary cirrhosis and end-stage liver disease. In this paper by Pares et al., the authors evaluate the effect of long-term use of bezafibrate in patients with primary biliary cholangitis (PBC) and inadequate response to UDCA. They found that addition of bezafibrate led to normalization of serum alkaline phosphatase in half of the study subjects and major improvement in pruritus. Here we discuss these findings and place them in context with current knowledge about fibrates in PBC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29311728     DOI: 10.1038/ajg.2017.432

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

1.  Primary biliary cirrhosis.

Authors:  Keith D Lindor; M Eric Gershwin; Raoul Poupon; Marshall Kaplan; Nora V Bergasa; E Jenny Heathcote
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

2.  EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.

Authors: 
Journal:  J Hepatol       Date:  2017-04-18       Impact factor: 25.083

3.  Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.

Authors:  T M E Davis; R Ting; J D Best; M W Donoghoe; P L Drury; D R Sullivan; A J Jenkins; R L O'Connell; M J Whiting; P P Glasziou; R J Simes; Y A Kesäniemi; V J Gebski; R S Scott; A C Keech
Journal:  Diabetologia       Date:  2010-11-04       Impact factor: 10.122

4.  Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.

Authors:  Sumeyye Samur; Matthew Klebanoff; Reiner Banken; Daniel S Pratt; Rick Chapman; Daniel A Ollendorf; Anne M Loos; Kathleen Corey; Chin Hur; Jagpreet Chhatwal
Journal:  Hepatology       Date:  2017-01-17       Impact factor: 17.425

5.  Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.

Authors:  C Levy; J A Peter; D R Nelson; J Keach; J Petz; R Cabrera; V Clark; R J Firpi; G Morelli; C Soldevila-Pico; K Lindor
Journal:  Aliment Pharmacol Ther       Date:  2010-11-17       Impact factor: 8.171

6.  Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis.

Authors:  Alla Y Grigorian; Houssam E Mardini; Christophe Corpechot; Raoul Poupon; Cynthia Levy
Journal:  Clin Res Hepatol Gastroenterol       Date:  2015-04-14       Impact factor: 2.947

7.  How the concept of biochemical response influenced the management of primary biliary cholangitis over time.

Authors:  W J Lammers; M Leeman; C I J Ponsioen; K Boonstra; K J van Erpecum; F H J Wolfhagen; J Ph Kuyvenhoven; J M Vrolijk; J P H Drenth; E M Witteman; C M J van Nieuwkerk; B W van der Spek; B J M Witteman; G W Erkelens; M A M T Verhagen; S A C van Tuyl; A C Poen; J T Brouwer; F Ter Borg; G H Koek; T J M van Ditzhuijsen; B E Hansen
Journal:  Neth J Med       Date:  2016-07       Impact factor: 1.422

8.  Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.

Authors:  Anna Reig; Pilar Sesé; Albert Parés
Journal:  Am J Gastroenterol       Date:  2017-10-10       Impact factor: 10.864

9.  Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.

Authors:  Willem J Lammers; Henk R van Buuren; Gideon M Hirschfield; Harry L A Janssen; Pietro Invernizzi; Andrew L Mason; Cyriel Y Ponsioen; Annarosa Floreani; Christophe Corpechot; Marlyn J Mayo; Pier M Battezzati; Albert Parés; Frederik Nevens; Andrew K Burroughs; Kris V Kowdley; Palak J Trivedi; Teru Kumagi; Angela Cheung; Ana Lleo; Mohamad H Imam; Kirsten Boonstra; Nora Cazzagon; Irene Franceschet; Raoul Poupon; Llorenç Caballeria; Giulia Pieri; Pushpjeet S Kanwar; Keith D Lindor; Bettina E Hansen
Journal:  Gastroenterology       Date:  2014-08-23       Impact factor: 22.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.